Ardelyx (ARDX) to Release Quarterly Earnings on Thursday

Ardelyx (NASDAQ:ARDX) is expected to issue its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $100.4380 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. The firm had revenue of $97.66 million for the quarter, compared to analysts’ expectations of $82.69 million. Ardelyx had a negative return on equity of 36.57% and a negative net margin of 14.60%.The company’s revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.07) EPS. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Price Performance

NASDAQ ARDX opened at $5.11 on Wednesday. The business’s fifty day moving average price is $5.80 and its 200-day moving average price is $4.84. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -22.22 and a beta of 0.67. The company has a debt-to-equity ratio of 1.44, a current ratio of 4.30 and a quick ratio of 4.03. Ardelyx has a 1-year low of $3.21 and a 1-year high of $6.78.

Insider Buying and Selling

In related news, insider Laura A. Williams sold 80,000 shares of the firm’s stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $6.12, for a total value of $489,600.00. Following the transaction, the insider directly owned 366,322 shares of the company’s stock, valued at approximately $2,241,890.64. This trade represents a 17.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Justin A. Renz sold 7,037 shares of the firm’s stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $5.93, for a total value of $41,729.41. Following the sale, the chief financial officer directly owned 409,052 shares in the company, valued at approximately $2,425,678.36. This represents a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 165,551 shares of company stock worth $996,917 in the last quarter. Company insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

A number of institutional investors and hedge funds have recently bought and sold shares of ARDX. Bank of America Corp DE grew its position in Ardelyx by 88.8% in the second quarter. Bank of America Corp DE now owns 5,527,988 shares of the biopharmaceutical company’s stock worth $21,670,000 after acquiring an additional 2,600,080 shares in the last quarter. AQR Capital Management LLC grew its position in Ardelyx by 47.0% in the second quarter. AQR Capital Management LLC now owns 2,312,363 shares of the biopharmaceutical company’s stock worth $9,064,000 after acquiring an additional 739,300 shares in the last quarter. Balyasny Asset Management L.P. grew its position in Ardelyx by 88.9% in the second quarter. Balyasny Asset Management L.P. now owns 1,069,856 shares of the biopharmaceutical company’s stock worth $4,194,000 after acquiring an additional 503,420 shares in the last quarter. First Trust Advisors LP purchased a new position in Ardelyx in the second quarter worth about $1,316,000. Finally, Goldman Sachs Group Inc. grew its position in Ardelyx by 10.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company’s stock worth $11,680,000 after acquiring an additional 221,486 shares in the last quarter. 58.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ARDX has been the topic of several research analyst reports. Wedbush reissued an “outperform” rating and set a $14.00 price target (up from $13.00) on shares of Ardelyx in a report on Tuesday, August 5th. Wall Street Zen raised Ardelyx from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Piper Sandler increased their price target on Ardelyx from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. UBS Group set a $12.00 target price on Ardelyx in a report on Tuesday, August 5th. Finally, Raymond James Financial began coverage on Ardelyx in a report on Wednesday, September 3rd. They issued a “strong-buy” rating and a $14.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Ardelyx currently has an average rating of “Moderate Buy” and an average price target of $11.70.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.